Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Krish Patel, MD, Jean-Marie Michot, MD, Asher A. Chanan-Khan, MD, Gilles A. Salles, MD PhD, Guillaume Cartron, MD PhD, Frederic Peyrade, MD, Reda Bouabdallah, Erin G. Reid, MD MS, Sheeba K. Thomas, MD, William G. Wierda, MD PhD, David Liebowitz, MD, John M. Pagel, MD PhD DSc, Vincent Ribrag, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, Thomas Ly, PhD, Tycel J. Phillips, MD

Blood (2019) 134 (Supplement_1): 4079.

https://doi.org/10.1182/blood-2019-128564

Published: 2019

Journal Articles

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

Farhad Ravandi, MD, Asad Bashey, MD PhD, James M. Foran, MD, Wendy Stock, MD, Raya Mawad, MD, William Blum, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, K. Gary J. Vanasse, MD, Thomas Ly, PhD, Hagop M. Kantarjian, MD, Bhavana Bhatnagar, DO, Koichi Takahashi, MD, Alice S. Mims, MD

Blood (2018) 132 (Supplement 1): 763.

https://doi.org/10.1182/blood-2018-99-119786

Published: 2018

Journal Articles

CD80 (B7.1) Is Expressed On Both Malignant B Cells and Tumor Infiltrating T Cells in Non-Hodgkin's Lymphomas.

Shabnam Tangri, Ph.D., Naveen Dakappagari, Annalee Estrellado, Andrew P. Weng, MD, PhD, Elizabeth Holmes, M. Wayne Saville, MD, FACP, FRCPA, Kandasamy Hariharan, Steffan Ho

Blood (2009) 114 (22): 1953.

https://doi.org/10.1182/blood.V114.22.1953.1953

Published: 2009

Journal Articles

Evaluation of Humoral Immune Responses to Vaccination with Tetanus Toxoid and KLH in Rituximab-Treated Follicular Non-Hodgkin’s Lymphoma Patients Compared to Healthy Volunteers

M. Wayne Saville, MD, FACP, FRCPA, Nancy Valente, MD, Rachelle Perea, Kye Gilder, Judith Berlfein, Ilya Zyuzgin, PhD, David Belada, MD., PhD., Andre Banat, MD, MBA, Tudor Ciuleanu, MD

Blood (2008) 112 (11): 3066.

https://doi.org/10.1182/blood.V112.11.3066.3066

Published: 2008

Journal Articles

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90 Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90 Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma (NHL).

Andrew M. Evens, DO, MS, Stewart Spies, MD, David Patton, MS, Irene Helenowski, MS, Borko Jovanovic, PhD, Sarah Miyata, RN, ACNP, Elizabeth Hamilton, RN, CNP, M. Wayne Saville, MD, Richard A. Miller, MD, Jane N. Winter, MD, Leo I. Gordon, MD

Blood (2007) 110 (11): 2558.

https://doi.org/10.1182/blood.V110.11.2558.2558

Published: 2007

Journal Articles

Role of Different Frontline Regimens in Achieving Complete Response in Follicular Lymphoma: A Meta-Analysis of CR Rate and Its Relation to Hazard Rate for Disease Progression.

M. Wayne Saville, John P. Leonard, John D. Hainsworth, Mitchell R. Smith, Mohamed Darif, Craig Park, Stephen J. Schuster

Blood (2006) 108 (11): 2754.

https://doi.org/10.1182/blood.V108.11.2754.2754

Published: 2006

Journal Articles

Rituximab and Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy May Be Feasible Options in Patients with Low-Grade Lymphoma of the Orbit.

Bita Esmaeli, MD, Barbara Pro, MD, M. Wayne Saville, MD, Peter McLaughlin, MD

Blood (2005) 106 (11): 4792.

https://doi.org/10.1182/blood.V106.11.4792.4792

Published: 2005

Journal Articles

No clinical evidence for CD4 + cell depletion caused by rituximab

M. Wayne Saville, Mark C. Benyunes, Pratik S. Multani

Blood (2003) 102 (1): 408–409.

https://doi.org/10.1182/blood-2003-03-1005

Published: 2003

NARROW

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

CD80 (B7.1) Is Expressed On Both Malignant B Cells and Tumor Infiltrating T Cells in Non-Hodgkin's Lymphomas.

Evaluation of Humoral Immune Responses to Vaccination with Tetanus Toxoid and KLH in Rituximab-Treated Follicular Non-Hodgkin’s Lymphoma Patients Compared to Healthy Volunteers

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90 Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90 Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma (NHL).

Role of Different Frontline Regimens in Achieving Complete Response in Follicular Lymphoma: A Meta-Analysis of CR Rate and Its Relation to Hazard Rate for Disease Progression.

Rituximab and Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy May Be Feasible Options in Patients with Low-Grade Lymphoma of the Orbit.

No clinical evidence for CD4 + cell depletion caused by rituximab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only